LOGIN  |  REGISTER
Astria Therapeutics

Lifecore Biomedical to Participate in Craig-Hallum Bioprocessing Conference

September 12, 2024 | Last Trade: US$6.36 0.07 -1.09

CHASKA, Minn., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that Paul Josephs, the Company’s president and chief executive officer, and Ryan Lake, the Company’s chief financial officer, will be the featured speakers in a fireside chat at the upcoming Craig-Hallum Bioprocessing Conference. The conference will take place virtually on September 19, 2024.

Details are as follows:

  • Craig-Hallum Bioprocessing Conference
    Details: Mr. Josephs and Mr. Lake will participate in a fireside chat and in 1-on-1 meetings
    Conference Dates: September 19, 2024
    Fireside Chat Timing: 3:30 p.m. Eastern on Thursday, September 19, 2024
    Format: Virtual

Following the fireside chat, a webcast replay will be available via a link on Lifecore’s investor website on the Investor Events & Presentations page at: https://ir.lifecore.com/events-presentations.

About Lifecore Biomedical

Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the Company, visit Lifecore’s website at www.lifecore.com.

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page